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Seizure models have demonstrated that neuroinflammation and neurodegeneration are preponderant characteristics of epilepsy.
Considering the lack of clinical studies, our aim is to investigate the extrinsic pathway of apoptosis in pharmacoresistant temporal
lobe epilepsy (TLE) associated with hippocampal sclerosis (HS) patients, TLE(HS). By a specific death receptor-mediated apoptosis
array plate, 31 upregulated targets were revealed in the sclerotic hippocampus from TLE(HS) patients. Amongst them are the
encoding genes for ligands (FASLG, TNF, and TNFSF10) and death receptors (FAS, TNFRSF1A, TNFRSF10A, and TNFRSF10B).
In addition, we evaluated the hippocampal relative mRNA expression of the two TNF receptors, TNFRSF1A and TNFRSF1B, in
patients, being both upregulated (𝑛 = 14; 𝑃 < 0.01 and 𝑃 < 0.04, resp.) when compared to the post mortem control group (𝑛 = 4).
Our results have clearly suggested that three different death receptor apoptotic systemsmay be associated with themaintenance and
progression of TLE-associated HS: (1) TNF-TNFRSF1A, (2) FASLG-FAS, and (3) TNFSF10-TNFRSF10A/B.Their effects on epilepsy
are still scarcely comprehended. Our study points out to TNF and TNF receptor superfamily pathways as important targets for
pharmacological studies regarding the benefits of an anti-inflammatory therapy in these patients.
1. Introduction
The connection between neurodegeneration and inflamma-
tion in the epileptic brain has emerged as an important axis
for the comprehension of the pathomechanisms involved in
seizure associated neuronal cell death. Hippocampal sclerosis
(HS) is the main pathohistological abnormality found in
resected tissue from temporal lobe epilepsy (TLE) patients.
It is characterized by astrogliosis: an irregular proliferation of
astrocytes due to the apoptosis of nearby neurons [1]. Several
studies assert that inflammation has a crucial role in epilepto-
genesis [2], and there is a high probability that hippocampal
chronic inflammation could exacerbate astrogliosis in TLE
patients.
Apoptosis is divided into two main specific pathways:
intrinsic and extrinsic. In spite of requesting particular
triggers to start a cascade of molecular events, both pathways
converge in the activation of CASP3, and both are present in
TLE-associated HS. The apoptotic intrinsic signaling path-
ways are initiated by non-receptor-mediated intracellular
signals (e.g., DNAdamage, radiation) that result in changes in
the inner mitochondrial membrane. Seizures by themselves
can represent an interesting example of these kinds of
signals. One of the primary events in hippocampal seizure-
induced apoptosis is the excessive release of glutamate with
consequent intracellular calcium overload, culminating in
downstream swelling and rupture of intracellular organelles
and activated proteolytic enzymes leading to cell death [3].
Unlike the intrinsic signaling pathways that initiate apop-
tosis, the extrinsic signaling pathways involve transmem-
brane receptor-mediated interactions. These include death
receptorswhich aremembers of theTNF receptor gene super-
family [4]. Apoptotic or survival signals are the consequence
of the death receptor family activation by death ligands.
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Various members of this family have been described thus
far, including TNFRSF1A, FAS, TNFRSF25, TNFRSF10A,
TNFRSF10B, and TNFRSF21 [5]. The execution pathway can
be initiated by these receptors through CASP8 or CASP10
whose activation could trigger the proapoptotic proteins BID
or BAX, via TP53, culminating in a cross talk with the
mitochondrial or intrinsic pathway of apoptosis [4].
Recurrent seizures induce not only neuronal cell loss
but also inflammation [6]. However, neuronal cell loss is
not a prerequisite for inflammation to happen; rather, the
liberation of proinflammatory cytokines can contribute to
cell death [7], and dying cells may perpetuate inflammation
[6]. Previously, we reported a marked TNF upregulation
in TLE(HS) patients [8], which is indicative of chronic
hippocampal inflammation.
We believe that the neuronal apoptosis through death
receptor pathways highlights the key molecular events
involved in triggering astrogliosis and TLE-associated HS.
Understanding which are the soluble mediators and the
molecular mechanisms crucially involved in the link between
inflammation and neuronal cell death is instrumental to shed
light on how seizures may contribute to HS in epilepsy and to
identify new therapeutic targets for the treatment and cure of
pharmacoresistant epilepsy, particularly in TLE(HS) patients.
2. Methods
2.1. Subjects and Tissue Collection. Ethical approval was
certified by the “Comiteˆ de E´tica da Faculdade de Cieˆncias
Me´dicas da Unicamp” (CEP n 470/2003). Subjects’ data
was reported in a recent study [8]. The present study was
performed with the same patient and post mortem control
samples. Briefly, TLE and HS were detected by teleme-
try/video electroencephalogram and magnetic resonance
image, respectively, in 14 patients. Due to the pharmacoresis-
tance of the syndrome, they went through an amygdalohip-
pocampectomy for treatment. All hippocampal tissue sam-
ples were immediately collected and divided into two parts.
One portion was fixed for histopathological analysis and
HS/astrogliosis was confirmed in all of them [H&E staining
and the terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay; data not shown]. The second
portion was immediately snap-frozen in liquid nitrogen after
surgery and stored at −80∘C until RNA isolation.
Four post mortem control hippocampal tissue samples (1
female, 3 males; 22.75 ± 5.56 years old, ranging from 19 to 31)
were kindly provided by the “Instituto Me´dico Legal, IML”
(Forensic Institute) of Campinas. Post mortem control sub-
jects passed away instantaneously or quickly. Although their
deaths were traumatic, which runs against the occurrence
and progression of neuroinflammation, neurological findings
were not detected and the post mortem delay averaged 7.8 h
(range: 6.0–9.0 h).
2.2. Gene Expression. All reagents were purchased from
Thermo Fisher Scientific Inc.; Waltham, MA 02451,
USA (former Life Technologies; Foster City, CA 94404,
USA).
2.2.1. RNA Extraction, Array Gene Expression, and RT-
qPCR. Total RNA extraction and RT-qPCR were carried out
according to our previous work [8]. TRIzol Reagent was
used for RNA extraction according to the manufacturer’s
instructions. The RNA integrity number (RIN) average in
control and patient groups was 7.525 ± 0.5437 and 6.155 ±
0.2484, respectively. Afterwards, 1 𝜇g of total RNA of each
sample was reverse transcribed into cDNA using 200U of
Superscript III Reverse Transcriptase and 3𝜇g of Random
Primers. Sterilized and filtered DEPC treated water was used
in all RNA procedures.
To identify potential targets associated with apoptosis
through death receptor signaling, we used a TaqMan Array
HumanApoptosis through death receptors 96-well plate (PN:
4414105). The plate contained 44 assays of genes associated
with death receptor-mediated apoptosis and four assays of
reference gene (endogenous control) candidates (Table 1).
Gene names are in accordance with the approved symbol
from the HUGO Gene Nomenclature Committee (HGNC)
database. All assays were plated in duplicates: one for cDNA
pooled from the TLE(HS) patients (𝑛 = 12) versus the
other for cDNA pooled from the post mortem controls (𝑛 =
4). Among several factors which can influence 𝐶
𝑇
(cycle
threshold) and consequently qPCR results credibility, we
emphasized instrument calibration and cDNA quality. The
template concentration (e.g., concentration of total RNA
converted to cDNA) should always be homogeneous among
samples, particularly when working with pools. cDNA con-
centration and purity were assessed by spectrophotometry
(NanoDrop ND1000; NanoDrop Technologies, Wilmington,
DE).The cDNA concentration means were 858.1 ± 30.07 and
871.9 ± 27.10 for control and patient samples, respectively.
cDNAabsorbance (A260/A280) ranged from 1.84 to 1.90 con-
sidering all 16 samples. Reactions were carried out according
to manufacturer’s instructions. We used a total volume of
20𝜇L, comprising 10 𝜇L of TaqMan Gene Expression Master
Mix (Life Technologies) and 10 𝜇L of pooled cDNA diluted
in DNase-free water. The final concentration of the pooled
cDNA samples used was 10 ng in 10 𝜇L for each 20𝜇L PCR
reaction.
Two target genes were chosen to be tested sepa-
rately by subject: TNFRSF1A and TNFRSF1B (Assay ID:
Hs00153550 m1). The latter was not included in the array
plate. The PCR efficiency validation was also performed
according to our previous work [8]. The amplification effi-
ciencies were close to 1.0 (100%). cDNA samples derived
from the investigated genes were detected using an ABI
PRISM 7500 Sequence Detection system and TaqMan Gene
Expression Assays. For RT-qPCRs, reference genes were
selected according to Wierschke et al. [9]. Therefore, HPRT1
and the geometric mean of ENO2 and TBP were used as
our normalization factors. Both were indicated as being the
most stable reference genes in epileptogenic tissue [9]. Each
qPCR was run as triplicates with 10 ng cDNA sample in
6.25 𝜇L TaqMan Gene Expression Master Mix, 0.625 𝜇L of
the respective probe/primer mix and 0.625𝜇L purified and
deionized H
2
O. All reactions were run as triplicates, and
measurements with a difference of more than 0.3 𝐶
𝑇
-values
were excluded from analysis.
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Table 1: Array target genes: apoptosis through death receptors in TLE(HS).
Target genes
Symbol, approved name, and Assay ID Synonyms and aliases Function RQ
ACTA1
actin, alpha 1, skeletal muscle
Hs00559403 m1
NEM3, “nemaline myopathy type 3” Cell motility 1.12
ACTB
actin, beta
Hs99999903 m1
Cell motility 1.74
APAF1
apoptotic peptidase activating factor 1
Hs00559441 m1
APAF-1, CED4 Apoptosis induction byCASP3 activation 1.59
BAX
BCL2-associated X protein
Hs00180269 m1
BCL2L4 Apoptosis induction byCASP3 activation 1.50
BCL2
B-cell CLL/lymphoma 2
Hs99999018 m1
Bcl-2, PPP1R50, “protein phosphatase 1,
and regulatory subunit 50” Apoptosis inhibition 1.87
BID
BH3 interacting domain death agonist
Hs00609632 m1
Apoptosis induction 1.40
BIRC2
baculoviral IAP repeat containing 2
Hs01112284 m1
“Apoptosis inhibitor 1”, c-IAP1, cIAP1,
hiap-2, MIHB, “NFR2-TRAF signalling
complex protein”, and RNF48
Apoptosis inhibition 1.31
BIRC3
baculoviral IAP repeat containing 3
Hs00154109 m1
“Apoptosis inhibitor 2”, c-IAP2, cIAP2,
hiap-1, “inhibitor of apoptosis protein 1”,
MALT2, “mammalian IAP homolog C”,
MIHC, RNF49, and “TNFR2-TRAF
signaling complex protein”
Apoptosis inhibition 1.27
CASP2
caspase 2
Hs00234982 m1
ICH1, MGC2181, PPP1R57, and “protein
phosphatase 1, regulatory subunit 57”
Involved in the activation
cascade of caspases
responsible for apoptosis
execution
1.38
CASP3
caspase 3
Hs00234387 m1
Apopain, CPP32, CPP32B, and Yama
Involved in the activation
cascade of caspases
responsible for apoptosis
execution
1.44
CASP7
caspase 7
Hs00169152 m1
CMH-1, ICE-LAP3, and MCH3
Involved in the activation
cascade of caspases
responsible for apoptosis
execution; overexpression
promotes programmed cell
death
2.13
CASP8
caspase 8
Hs01018151 m1
Casp-8, FLICE, MACH, and MCH5
Most upstream protease of
the activation cascade of
caspases responsible for the
FAS mediated and
TNFRSF1A induced cell
death
2.45
CASP9
caspase 9
Hs00154260 m1
APAF-3, ICE-LAP6, MCH6, PPP1R56,
and “protein phosphatase 1, regulatory
subunit 56”
Involved in the activation
cascade of caspases
responsible for apoptosis
execution
1.55
CFLAR
CASP8 and FADD like apoptosis
regulator
Hs01116280 m1
c-FLIP, CASH, Casper, CLARP, FLAME,
FLIP, I-FLICE, and MRIT
Apoptosis regulator protein
as FAS mediated apoptosis
inhibitor
1.59
CHUK
conserved helix-loop-helix ubiquitous
kinase
Hs00175141 m1
IKBKA, IKK-alpha, IKK1, IKKA, and
NFKBIKA
Serine kinase. Essential role
in the NFkB signaling
pathway
1.22
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Table 1: Continued.
Target genes
Symbol, approved name, and Assay ID Synonyms and aliases Function RQ
DAXX
death-domain associated protein
Hs00154692 m1
DAP6
JNK pathway and apoptosis
mediator via MAP3K5 [FAS
and TGFBR2 (transforming
growth factor beta receptor
II) signaling]
1.53
DIABLO
diablo, IAP-binding mitochondrial
protein
Hs00219876 m1
DFNA64, DIABLO-S, FLJ10537,
FLJ25049, “second mitochondria-derived
activator of caspase”, and SMAC
Apoptosis promoter by
caspase activation in the
cytochrome
c/APAF1/CASP9 pathway
1.45
FADD
Fas associated via death domain
Hs00538709 m1
“Fas-associating death
domain-containing protein,”
“Fas-associating protein with death
domain,” GIG3, “growth-inhibiting gene
3 protein,” “mediator of receptor-induced
toxicity,” and MORT1
CASP8 and CASP10
apoptotic adaptor recruiter
to activated FAS and
TNFRSF1A
1.13
FAS
Fas cell surface death receptor
Hs00531110 m1
APO-1, CD95, and “TNF receptor
superfamily member 6”
Receptor with death
domain for FASLG 1.65
FASLG
Fas ligand
Hs00181225 m1
CD178, FasL Cytokine ligand for FAS 5.46
IKBKB
inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase beta
Hs00233287 m1
IKK-beta, IKK2, IKKB, and NFKBIKB NFkB activator 1.96
IKBKG
inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase gamma
Hs00415849 m1
FIP-3, FIP3, Fip3p, IKK-gamma, NEMO,
and ZC2HC9 NFkB activator 1.65
MAP3K5
mitogen-activated protein kinase kinase
kinase 5
Hs00178726 m1
“Apoptosis signal regulating kinase 1,”
ASK1, and MAPKKK5
Signal transduction
mediator by oxidative stress
and receptor-mediated
inflammatory signals
(TNF)
1.55
MAPK8
mitogen-activated protein kinase 8
Hs01548508 m1
JNK, JNK1, “JUN N-terminal kinase,”
and SAPK1
Stressed cell apoptosis
promoter through TP53
and YAP1
1.05
MAPK9
mitogen-activated protein kinase 9
Hs00177102 m1
JNK2, “Jun kinase,” p54a, and SAPK
Stressed cell apoptosis
promoter through TP53
and YAP1
0.86
NFKB1
nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1
Hs00765730 m1
KBF1, NF-kappaB, NF-kB1, NFkappaB,
NFKB-p50, p105, and p50
Rel protein-specific
transcription inhibitor
(105 kD) and DNA binding
subunit of the transcription
factor NFkB (50 kD)
1.50
NFKB2
nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
Hs00174517 m1
LYT-10, NF-kB2, p105, and p52 Subunit of the transcriptionfactor NFkB 3.21
NFKBIA
nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha
Hs00153283 m1
IkappaBalpha, IKBA, and MAD-3 NFkB inhibitor 2.36
NGF
nerve growth factor (beta polypeptide)
Hs01113193 m1
Ligand for NTRK1 and
NGFR; neuronal
proliferation,
differentiation and survival
regulator
0.90
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Table 1: Continued.
Target genes
Symbol, approved name, and Assay ID Synonyms and aliases Function RQ
NGFR
nerve growth factor receptor
Hs00609976 m1
CD271, “low affinity nerve growth factor
receptor,” p75NTR, “TNFR superfamily,
member 16,” and TNFRSF16
Neural cell death or
survival mediator 3.53
PARP1
poly(ADP-ribose) polymerase 1
Hs00242302 m1
PARP
DNA repair pathway
initiation; apoptosis
promoter in response to
genotoxic stress
1.51
RELA
v-rel avian reticuloendotheliosis viral
oncogene homolog A
Hs00153294 m1
p65 Subunit of the transcriptionfactor NFkB 2.02
TNF
tumor necrosis factor
Hs00174128 m1
DIF, “TNF superfamily, member 2,”
TNF-alpha, and TNFSF2
Multifunctional
proinflammatory cytokine
ligand for TNFRSF1A and
TNFRSF1B
39.96
TNFRSF10A
tumor necrosis factor receptor
superfamily member 10a
Hs00269492 m1
Apo2, CD261, DR4, and TRAILR-1
Receptor with death
domain for TNFSF10;
NFkB activator
2.39
TNFRSF10B
tumor necrosis factor receptor
superfamily member 10b
Hs00366278 m1
CD262, DR5, KILLER, TRAIL-R2,
TRICK2A, and TRICKB
Receptor with death
domain for TNFSF10; ER
stress-induced apoptosis
promoter; NFkB activator
1.55
TNFRSF10C
tumor necrosis factor receptor
superfamily member 10c
Hs00182570 m1
CD263, DcR1, LIT, TRAILR3, and TRID
Decoy receptor for
TNFSF10; apoptosis
inhibitor
4.82
TNFRSF10D
tumor necrosis factor receptor
superfamily member 10d
Hs00533560 m1
CD264, DcR2, TRAILR4, and TRUNDD
Decoy receptor for
TNFSF10; apoptosis
inhibitor
3.74
TNFRSF1A
tumor necrosis factor receptor
superfamily member 1A
Hs00205419 m1
CD120a, TNF-R, TNF-R-I, TNF-R55,
TNFAR, and TNFR60
Receptor with death
domain for TNF and LTA
(lymphotoxin alpha); NFkB
activator, apoptosis
mediator, and
inflammation regulator
3.07
TNFRSF21
tumor necrosis factor receptor
superfamily member 21
Hs00237054 m1
CD358, “death receptor 6,” and DR6
Receptor with death
domain; apoptosis
promoter
1.09
TNFRSF25
tumor necrosis factor receptor
superfamily member 25
Hs00187070 m1
APO-3, DDR3, DR3, LARD, TR3,
TRAMP, WSL-1, and WSL-LR
Receptor with death
domain for TNFSF12;
mediator of NFkB
activation and apoptosis
promoter
1.72
TNFRSF6B
tumor necrosis factor receptor
superfamily member 6b
Hs00234356 m1
DcR3, DCR3, M68, and TR6 Decoy receptor for FASLG;apoptosis inhibitor 2.54
TNFSF10
tumor necrosis factor superfamily
member 10
Hs00174664 m1
Apo-2L, CD253, TL2, and TRAIL
Cytokine ligand for
TNFRSF10A, TNFRSF10B,
TNFRSF10C, and
TNFRSF10D
2.50
TP53
tumor protein p53
Hs01034249 m1
LFS1, “Li-Fraumeni syndrome,” and p53
Tumor suppressor, growth
arrest, or apoptosis
promoter depending on the
physiological
circumstances and cell type
2.77
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Table 1: Continued.
Target genes
Symbol, approved name, and Assay ID Synonyms and aliases Function RQ
TRAF2
TNF receptor associated factor 2
Hs00184192 m1
TRAP3
Mediator of the
antiapoptotic signals from
TNF receptors; NFkB and
JNK activation regulator
1.54
List of all target genes investigated in the array, involved in the extrinsic apoptotic pathway. The gene expression data [relative quantification (RQ) column],
also shown in Figure 1, corresponds to the cDNA pooled from TLE(HS) patients (𝑛 = 12) versus the cDNA pooled from post mortem controls (𝑛 = 4).
The latter was used as a calibrator with gene expression equal to 1.0. The values in the table can be converted to fold change values, where the negative
inverse (−1/𝑥) is taken for values between 0 and 1 (e.g., 0.5 is converted to −2). Values greater than 1 will not be affected. A −2 value indicates that
the molecule is 2-fold downregulated. Only MAPK9 and NGF were downregulated. The reference gene candidates in the plate were 18S (eukaryotic 18S
rRNA; Hs99999901 s1), GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Hs99999905 m1), GUSB (glucuronidase, beta; Hs99999909 m1), and HPRT1
(hypoxanthine phosphoribosyltransferase 1; Hs99999908 m1) although only GAPDH and HPRT1 were effectively used as reference genes (in combination).
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Figure 1: Hippocampal expression of genes associated with apoptosis through death receptors in TLE(HS) patients versus post mortem
controls. The combination of GAPDH and HPRT1 was used as the reference gene. The pool of post mortem control samples (𝑛 = 4) was the
reference sample (calibrator) and its relative quantification (RQ) was always 1.0. Different colors represent gene expression in RQ values (or
fold-change values, when RQ is a positive number) and correspond to the following parameters: red = very upregulated (RQ ≥ 2.0); orange
= upregulated (1.99 ≥ RQ ≥ 1.5); gray = normal (1.49 ≥ RQ ≥ 0.67). None of the 44 target genes analyzed was downregulated (0.66 ≥ RQ ≥
0.51) or very downregulated (RQ ≤ 0.5).
2.3. Data Analysis. Relative gene expression data was gener-
ated and analyzed by the 7500 Software version 2.0.5 (Life
Technologies). The software GraphPad Prism 5 was used
for the statistical analysis (GraphPad Prism version 5.04 for
Windows, GraphPad Software, San Diego California USA,
⟨http://www.graphpad.com⟩).TheMann-Whitney𝑈 test was
used for comparison between data from the control group
(𝑛 = 4) versus the patient group (𝑛 = 14). For all analyses,
differences of 𝑃 < 0.05 were considered significant.
A molecular pathway related to differentially expressed
genes was created by the IPA-Ingenuity Pathway Analy-
sis (Ingenuity Systems, ⟨http://www.ingenuity.com⟩) appli-
cation via the “Core Analysis” function. The array data
sheet generated by the 7500 Software was uploaded into
the IPA application. The differentially expressed genes were
connected based on the reported association among genes or
proteins and their functional roles.
3. Results
Array gene expression quantifications are shown in Table 1
and Figure 1. From 44 target genes associated with apoptosis
through death receptors, we found 31 upregulated genes
(70.45%). Our criterion to define an upregulated gene was
based on an increase of aminimumof 50%onmRNA levels in
comparison to controls, which corresponds to a cutoff of 1.5-
fold change. Choosing a precise cutoff is always a challenge
in array studies and it is crucial to analyze results and select
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Figure 2: Hippocampal gene expression of TNFRSF1A and TNFRSF1B in TLE(HS) patients versus post mortem controls. HPRT1 and
ENO2/TBP were used as reference genes. One of the post mortem control samples was randomly chosen as the reference and its relative
quantification was always 1.0. All quantification data for the remaining samples, including controls and patients, was benchmarked to the
reference sample. Samples were separated in two groups: TLE(HS) patients (𝑛 = 14) and post mortem controls (𝑛 = 4). (a) Columns aremeans
with SD. Mann-Whitney 𝑈 tests were used for the comparison between groups. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01. (b) Marks are different geometric
figures, which represent the gene expression mean of the samples. The horizontal line is the mean of the group analyzed. Circles and squares
correspond to gene expression withHPRT1 as the reference.The two kinds of triangles correspond to gene expression with ENO2/TBP as the
reference.The red and green squares (outliers) correspond to TLE 09 and TLE 03 patients, respectively (see Table 1 in Teocchi et al., 2013 [8]).
the most important targets. Considering our previous study
on NFKB1 expression in the same group of TLE(HS) patients
(𝑛 = 14) [8], a 1.5 cutoff is statistically acceptable since the
NFKB1 expression in the array was exactly 1.5-fold.
The number of upregulated genes is narrowed to 15 if
a cutoff of 2.0 is considered (at least an augmentation of
100% onmRNA levels).This more conservative cutoff reveals
critical target genes that can be divided into 3 categories:
(1) ligands and receptors, (2) mediators, and (3) molecules
related to the transcription factor nuclear factor kappa B
(NFkB). Discussion will be guided by these categories and
focused on the controversies and novelties related to these
most upregulated targets.
Regardless of the cutoff or even the reference genes,
array TNF expression (39.96-fold) was very meaningful,
particularly in comparison to the expression of the other
genes. This significant overregulation led us to quantify
separately the expression of its receptors, TNFRSF1A and
TNFRSF1B, being both statistically upregulated (𝑃 < 0.01
and 𝑃 < 0.04, resp.) (Figure 2). In Figure 3, we proposed
a schematic pathway which involves TNF, TNFRSF1A, and
eight of the other 13 very upregulated genes.
4. Discussion
Inflammation, degeneration of neurons and HS are closely
related [10]. Recently, we reported a marked TNF upregula-
tion in TLE(HS) patients [8], which is indicative of chronic
hippocampal inflammation. The importance of this cytokine
as one of the main apoptosis “propellers” in TLE-associated
HS is reinforced by our Human Apoptosis through death
receptors array results (Table 1 and Figure 1) which show the
8 Mediators of Inflammation
A, E, L, RB (1)
A, E, LO, M, P, PD, RB,TR (55) A, PD, PP, RB (29)
A, E, L, P, PD, RB, T (61)
TP53 (includes EG: 22059)
TNFRSF10A
FASLG
RELA
TNF
A (1)
A, E, L, LO, M, PD, PP, RB, T (21)
L (1)
E (1)
A, RB (2)
PD, RB (4)
E (1)
E, PP, RB (3)
A, E (3)
PD (1)
E, RB (7)
L (2)
PP (1)
E (1)
E (1)
A, LO, PP, RB (11)
A, RB (2)
RB (1) L, LO, P, RB (2)
RB (1)
L (1)
A, PP (3)
TNFRSF1A
CASP8
CASP7
E (E, L, TR (3))
TNFRSF6B
NFKBIA
Figure 3: Apoptosis through death receptors: a signaling pathway in TLE(HS). This pathway was generated by the IPA software, based on
10 of the 15 upregulated genes (cutoff 2.0-fold change; see Table 1) in hippocampal tissues from TLE(HS) patients (𝑛 = 12) compared to
post mortem controls (𝑛 = 4). The biological relationship between two genes, represented as nodes, is shown as a line. Nodes with different
shapes indicate different functional class. The pathway created did not include the following genes: NFKB2, NGFR, TNFSF10, TNFRSF10C,
and TNFSF10D.The function “nervous relaxed” was used. A, activation; E, expression regulation; I, inhibition; L, proteolysis; LO, localization;
M, biochemical modification; P, phosphorylation; PD, protein-DNA interaction; PP, protein-protein interaction; RB, regulation of binding;
T, transcription; and TR, translocation.
upregulation of 31 related genes. They are associated with the
extrinsic apoptosis signaling pathway, among themmembers
of the TNF and TNF receptor gene superfamilies and several
factors which play a role in the cell death cascade. The vast
majority of them have never been quantified in patient’s
samples. Below, we present and discuss our finding which
suggests the involvement of these genes with neurodegener-
ation and the consequent astrogliosis in TLE(HS).
4.1. Apoptotic Systems: Ligands and Receptors
4.1.1.The TNF-TNFRSF1A Axis. There are few clinical studies
on the TNF system and its effects on epilepsy in spite of
intense investigation in animals. Several models indicate that
seizures induce the TNF expression in the brain [2, 11–14]
although some have shown no important TNF alterations
in plasma or CSF after different kinds of seizures [15–18].
In patients, Sinha et al. detected increased serum levels of
TNF and other cytokines in several epilepsy syndromes [19].
Our results for TLE(HS) patients differ from those on seizure
models only by the fact that the TNF mRNA increase does
not seem to be transiently enhanced. Some patients had their
last seizure several days before the surgery, implying that the
high TNF expression levels were happening often, suggesting
that chronic hippocampal inflammation could be intrinsic to
refractory TLE(HS).
The most controversial evidence on the TNF role in
epilepsywas raisedwhenBalosso et al. reported that intrahip-
pocampal injection of murine-recombinant TNF in mice
potently prevented seizures [20]. Moreover, transgenic mice
overexpressing TNF by astrocytes showed shorter seizures,
whereas deficient mice for TNF receptors had prolonged
seizures [20]. The dichotomic effect of TNF on seizures may
be related to the tissue microenvironment, including the
cellular source (neuronal versus glial) of TNF release, the
extent of TNF increase, its concentration and persistence in
tissue, and action through its two receptors expressed by the
targeted cells [14, 20, 21].
In the hippocampus, TNF is able to activate its two recep-
tors (TNFRSF1A and TNFRSF1B) to regulate cell-signaling
pathways [22, 23]. TNFRSF1A is ubiquitously expressed in
human tissues and is the principal signaling receptor for
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TNF. A cytoplasmic death domain, required for apoptotic
signaling pathways and NFkB activation, is present in this
major receptor. TNFRSF1B does not contain a death domain
and actuates in restricted biological processes, being mainly
expressed in immune cells. Through intracellular adaptors
called TRAFs (TNF Receptor-Associated Factors) associated
with this receptor, JNK (c-JunN-terminal kinase) is activated
during the cell survival induction through activation of NIK
(NFkB-inducing kinase), a downstream target of TRAF2.
Thus, TNFRSF1A has been involved in apoptosis activation,
whereas TNFRSF1B is implicated with activation of the NFkB
system [24–26]. Likewise, seizure model studies imply that
the TNFRSF1A pathway is associated with deleterious effects
and that the TNFRSF1B pathway is related to anticonvulsive
outcomes [14, 27].
Our hippocampal RT-qPCR results showed the upregu-
lation of both TNF receptors in TLE(HS) patients (Figure 2).
The deleterious consequences of TNFRSF1A action are well-
known; however, for TNFRSF1B, consequences are still
unclear. TNFRSF1B could be triggered as a survival mech-
anism to compensate for the extensive neuronal cell death
found in epilepsy-associated HS or its expression could
enable the harmful consequences of TNFRSF1A activation
[28]. These authors demonstrated that TNFRSF1B signifi-
cantly decreased the TNF concentration required for cell
death without the generation of an intracellular signal.
Instead, TNFRSF1B modulated the rate of TNF association
with TNFRSF1A, possibly by increasing the local concen-
tration of TNF at the cell surface through rapid ligand
association and dissociation. Functional experiments are
necessary to verify this finding in brain cells and clarify the
role of TNFRSF1B in TLE(HS). Furthermore, these authors
proposed that other cell-surface receptors, such as NGFR,
may utilize an analogous “ligand passing” mechanism. Our
array results showed the upregulation of NGFR (3.53-fold).
Increased expression of NGFR in hippocampal neurons of
TLE patients has already been described [29].
4.1.2. The FAS-FASLG Axis. FASLG triggers apoptosis by
binding to FAS [30]. Our finding showed the upregulation
of both FAS (1.65-fold) and FASLG (5.46-fold), which rep-
resents an important apoptotic system scarcely investigated
in clinical cases. Only one study reported an augmentation
of FAS in the sclerotic hippocampus from TLE patients [31].
In animals, seizures induced a significant augmentation in
FAS expression within the ipsilateral hippocampus from 4 to
24 h after levels returned to baseline [32]. Similarly, increased
expression of both FasmRNA and protein were evident in the
adult rat brain from4 h to 5 days after the onset of kainic acid-
induced seizures and neurons with increased FAS expression
were also immunoreactive for TP53 [33]. Induced by kainate,
FASLG expression increased rapidly at 6 h and returned to
the basal level at 3 days in CA1 and CA3/DG (dentate gyrus)
hippocampal regions [30, 34].
FASLG was the second most upregulated gene according
to our results (Figure 1). Considering the chronic status of
our patients, this cytokine does not appear to have a tran-
sient expression in pharmacoresistant TLE(HS) and might
contribute to neuronal loss, being the FAS-FASLG pathway
an interesting target for pharmacological studies. In addition,
we found that TNFRSF6Bwas also overregulated in TLE(HS)
patients (2.54-fold). The encoded protein by TNFRSF6B is
assumed to play a regulatory role in suppressing FASLG-
mediated cell death. It acts as a decoy receptor that competes
with death receptors for ligand binding [35] (Figure 3). We
have not found any studies regarding the association between
TNFRSF6B expression and epilepsy.
4.1.3. The TNFSF10-TNFRSF10A/B Axis. Besides apoptosis
mediated by TNF and FASLG and its receptors, TNFSF10
is another potent inducer of apoptosis [36, 37]. Both
apoptosis-inducing and nonapoptosis-inducing membrane-
bound receptors have been described for TNFSF10. Only
TNFRSF10A and TNFRSF10B are able to generate a death
signal [38, 39], while TNFRSF10C and TNFRSF10D are
truncated and have been proposed to function as decoy
receptors by binding TNFSF10 without producing a death
signal, thereby inhibiting apoptosis [39, 40]. Our results on
gene expression accentuate the importance of TNFSF10 (2.50-
fold) and its upregulated receptors (Figure 1).Theyhave never
been quantified by RT-qPCR in human TLE hippocampal
samples. In brain tissues from TLE patients, Do¨rr and
colleagues did not detect the expression of TNFSF10, but both
apoptosis-inducing and non-apoptosis-inducing receptors
were expressed on neurons, astrocytes, and oligodendrocytes,
which indicate their possible susceptibility to TNFSF10-
mediated apoptosis [41]. On the other hand, a significant
increase on TNFSF10 expression in both patients and animals
(seizure model) has been reported [42]. In accord with our
results, it is conceivable that there is an important action of
TNFSF10 and its receptors in TLE(HS)-associated neuronal
apoptosis. The expression and regulation of these receptors
might be crucial for death or survival of an individual
cell, since both apoptosis-mediating and apoptosis-blocking
receptors were present on the different brain parenchymal
cells [37, 41]. Our data per se shows an overview on this
apoptotic system and is complemented by the two previously
discussed studies on proteins.
4.2. Apoptotic Mediators: Caspases and TP53. We found
elevated mRNA levels for CASP7, CASP8, and CASP9 in
our TLE(HS) samples (Table 1 and Figure 1). This finding
extends and reinforces protein data from seizure models and
human epileptogenic tissue studies, which have reported a
deregulated expression of caspases [32, 43–46]. It is well-
known that sequential activation of caspases plays a central
role in the execution phase of cell apoptosis.
CASP7 is an effector, responsible for cleaving important
apoptotic intracellular substrates. Yamamoto et al. found X-
linked inhibitor of apoptosis (XIAP) binding CASP7 in TLE
brain, suggesting ongoing antiapoptotic responses, which
might be impeding caspases from inducing apoptosis [46].
XIAP can only bind activated CASP7 to modulate its activity
[47], and XIAP expression is regulated after experimental
seizures [48]. Their finding reinforces the evidence for
active CASP7 in the TLE hippocampus. CASP8 is a key
initiator of apoptosis via death receptor-mediated pathways,
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capable of inducing apoptosis by directly processing exe-
cutioner caspases [32]. In a seizure model, its inhibition
significantly reduced neuronal apoptosis, accompanied by
a decrease of tBID (truncated BID), cleaved CASP9, and
cytosol cytochrome c [45]. Our results are in agreement
with the studies mentioned and emphasize the importance
of CASP7 and CASP8 in TLE(HS) (Figure 3).
ATp53 overexpression occurred alongwith excitotoxicity
in an adult rat brain within hours after systemic adminis-
tration of glutamate analogue kainic acid [49]. Years later
and after several other reports on altered TP53 expression in
seizuremodels, including the alreadymentioned study of Tan
and colleagues [33], Xu et al. found TP53 positive cells in the
sclerotic hippocampus from TLE patients [31]. In the same
year, Engel and colleagues detected significantly higher levels
of TP53 byWestern blotting in hippocampal tissues fromTLE
patients [50]. Our result on the elevated TP53 mRNA level
extends and reinforces this data. It is still unclear if TP53
could function as a potential target for protection in seizure-
induced neuronal death since TP53 regulates a large number
of genes, which would need to be carefully evaluated [31].
4.3. Subunits and Regulators of the Transcription Factor
NFkB. As previously reported, we found that NFKB1 was
upregulated in TLE(HS) patients [8]. In the present study, our
array results showed thatNFKB1was 1.5-fold more expressed
than controls. Several other genes related to the NFkB com-
plex, such as IKBKB (1.96-fold), IKBKG (1.65-fold), NFKB2
(3.21-fold), NFKBIA (2.36-fold), and RELA (2.02-fold) also
showed an increased expression (Figure 1). Taken together,
our finding clearly emphasizes the NFkB involvement in
TLE(HS) physiopathology (Figure 3). In addition, protein or
mRNA expression data on those molecules is scarce, even
from seizure models.
A number of signal transduction events, initiated by
inflammation, immunity, differentiation, cell growth, tumo-
rigenesis, and apoptosis, converge on NFkB activation [51].
This pleiotropic transcription factor, present in practically all
cell types, is a homo- or heterodimeric complex formed by
the Rel-like domain-containing proteins RELA/p65, RELB,
NFKB1/p105, NFKB1/p50, REL, and NFKB2/p52. The het-
erodimeric p65-p50 complex appears to be the most com-
mon. NFKBIA and NFKBIB (I-kappa-B proteins) inhibit the
NFkB complex by trapping it in the cytoplasm [51]. The
kinases IKBKA and IKBKB mark I-kappa-B proteins for
destruction via the ubiquitination pathway, thereby allowing
activation of the NFkB complex. IKBKG is a regulatory
subunit of the inhibitor of kappa B kinase (IKK) core complex
which phosphorylates NFkB inhibitors, leading to the dis-
sociation of the inhibitor/NFkB complex and ultimately the
degradation of the inhibitor [51].Our finding shows that there
is a disturbed expression of activators and repressors of the
NFkB complex. Further studies are necessary to understand
the actual role of NFkB in TLE(HS).
5. Conclusions
We have demonstrated the upregulation of various genes
associated with the apoptosis through death receptor sig-
naling in the hippocampus from TLE(HS) patients. The
expression of the vast majority of these genes was studied
for the first time in hippocampal human samples despite
previous protein results, mainly from seizure models. Our
data reveals that both TNF receptor genes (TNFRSF1A and
TNFRSF1B) are overexpressed in patients. As key factors in
the TNF-induced apoptosis, they may play a crucial role in
hippocampal neuroinflammation and neurodegeneration.
Additionally, our results clearly suggest that three dif-
ferent death receptor apoptotic systems may be associated
with the maintenance and progression of TLE-associated
HS: (1) TNF-TNFRSF1A, (2) FASLG-FAS, and (3) TNFSF10-
TNFRSF10A/B. Their effects on epilepsy are still scarcely
comprehended. Other targets, such as the NFkB subunits and
regulators or the decoy receptor of FAS, TNFRSF6B, whose
gene upregulation has never been associated with epilepsy,
should be investigated. The understanding of these signaling
pathways is essential for the development of new antiepileptic
drugs and opens several possible avenues of research that will
help us to understand the complex pathophysiology in HS.
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